IDEAYA Biosciences, Inc. (IDYA), a precision medicine oncology company, Friday announced the grant of non-qualified stock options to two newly hired employees on January 30, 2025.
The total grant was for 62,800 shares of common stock under the company's 2023 Employment Inducement Incentive Award Plan. These stock options were granted as an inducement for the individuals to join IDEAYA, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of $23.88 per share, the closing price of IDEAYA's stock on the date of grant.
The options have a 10-year term and will vest over four years, with 25 percent vesting on the first anniversary and the remaining 75 percent vesting in monthly installments over the next three years, subject to continued service.
IDEAYA Biosciences focuses on discovering and developing targeted therapeutics in oncology, applying a precision medicine approach to identify patient populations that will benefit most from its therapies.
Currently, IDYA is trading at $24.40, up by 2.18 percent on Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.